On November 20, 2026 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, reported the pivotal Phase 3 TroFuse-015 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) licensed from Kelun-Biotech, met its primary endpoint of overall survival (OS) compared to treatment of physician’s choice (TPC, consisting of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel) in the treatment of patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who have received two or more prior lines of systemic therapy. TroFuse-015 represents the first time a TROP2-directed ADC has demonstrated an OS benefit in a global Phase 3 trial in this patient population, where there is significant unmet need. These data will be presented at an upcoming medical meeting and shared with regulatory authorities.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At final analysis, sac-TMT demonstrated a statistically significant and clinically meaningful improvement in OS compared to TPC for these patients who have received two or more prior lines of systemic therapy. Results were generally consistent across subgroups regardless of TROP2 expression status. Sac-TMT did not meet the secondary endpoint of progression-free survival (PFS) assessed by blinded independent central review (BICR). Additionally, sac-TMT showed a nominally improved benefit in objective response rate (ORR), a secondary endpoint, favoring sac-TMT compared with TPC, but this was not formally tested under the prespecified analysis plan. The safety profile was consistent with what has been observed in previously reported studies of sac-TMT; no new safety signals were observed.
"Sac-TMT is the first TROP2 ADC to improve OS in a global Phase 3 study in advanced gastroesophageal adenocarcinoma compared to TPC, demonstrating its potential in a particularly challenging disease setting," said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. "There is a tremendous unmet need for therapies that can improve survival for these patients. We look forward to discussing these data with regulatory authorities and sharing with the scientific community on behalf of patients who may benefit."
TroFuse-015 also marks the second positive Phase 3 study from Merck’s TroFuse clinical development program for sac-TMT. The program currently consists of 18 ongoing global Phase 3 trials across multiple tumor types, the broadest range of disease and treatment settings compared to any TROP2-directed ADC to date. The program is evaluating sac-TMT across a diverse range of tumor types, including endometrial, bladder, breast, cervical, gastric, non-small cell lung and ovarian cancers, and it spans early-to-late-stage disease as both monotherapy and in combination with immunotherapies. Within the program, 14 of the 18 Phase 3 studies are pursuing first-in-class opportunities to address unmet medical needs, including TroFuse-015.
About TroFuse-015
TroFuse-015 is a randomized, open-label, multicenter, global Phase 3 trial (ClinicalTrials.gov, NCT06356311) evaluating the efficacy and safety of the TROP2-directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) compared to the treatment of physician’s choice (TPC) in participants with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who have received two or more prior lines of systemic therapy. The trial enrolled 473 patients who were randomized to receive either sac-TMT or TPC, consisting of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. Sac-TMT (4 mg/kg) was administered on Days 1, 15 and 29 of each six-week treatment cycle. Trifluridine-tipiracil (35 mg/m²) was administered orally twice daily on Days 1-5 and 8-12 of each four-week treatment cycle. Irinotecan (150 mg/m²) was administered on Days 1 and 15 of each four-week treatment cycle. Paclitaxel (80 mg/m²) was administered on Days 1, 8 and 15 of each four-week treatment cycle. Docetaxel (75 mg/m²) was administered on Day 1 of each three-week treatment cycle.
The study has a primary endpoint of overall survival. Secondary endpoints include progression-free survival, objective response rate, and duration of response.
About sacituzumab tirumotecan (sac-TMT)
Sac-TMT is an investigational TROP2-directed ADC with a belotecan-derived topoisomerase I inhibitor payload and a unique bifunctional linker designed with the potential to maximize payload delivery to tumor cells and minimize payload loss while circulating in the body.
TROP2 is overexpressed on tumor cells compared to healthy cells in many common cancers, and through the TroFuse clinical development program, Merck is evaluating sac-TMT in 18 ongoing global Phase 3 trials across multiple tumor types, the broadest range of disease and treatment settings compared to any TROP2-directed ADC to date. The TroFuse development program spans early-to-late stage disease in more than nine disease areas and includes more than 15,000 patients worldwide. Numerous Phase 3 trials are exploring sac-TMT as monotherapy and in combination with immunotherapies, aiming to improve survival and quality of life for patients with advanced and earlier-stage cancers.
About Gastroesophageal Adenocarcinoma
Gastroesophageal adenocarcinoma comprises gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinomas (EAC).
Gastric (stomach) cancer often does not cause symptoms in its early stages, making it difficult to detect before the disease has advanced. Most gastric cancers are adenocarcinomas, accounting for approximately 90% to 95% of gastric malignancies, which develop from cells in the innermost lining of the stomach, known as the mucosa. In the U.S., it is estimated there will be approximately 31,500 new cases of gastric cancer and 10,700 deaths from the disease in 2026. Gastric cancer accounts for approximately 1.5% of all new cancers diagnosed in the U.S. each year.
Esophageal cancer starts when cells in the lining of the esophagus begin to grow out of control. In the U.S., about 68% of all new cases of esophageal cancer are EAC, and it is estimated there will be more than 14,300 new cases of EAC in 2026. Approximately 42% of EAC patients in the U.S. are diagnosed at the distant disease stage.
(Press release, Merck & Co, NOV 20, 2026, View Source [SID1234675036])